Combination chemotherapy with vincristine (NSC-67574), procarbazine (NSC-77213), prednisone (NSC-10023) with or without nitrogen mustard (NSC-762)(MOPP vs OPP) in children with recurrent brain tumors

Seventy-three patients under 18 years of age with a recurrent central nervous system tumor were randomized to receive combination chemotherapy with MOPP or OPP. Patients were stratified according to the tumor type into four major disease categories: (1) medulloblastoma, (2) astrocytoma and other glioma, (3) ependymoma, and (4) miscellaneous tumors to provide equal distribution of patients for each treatment within each disease category. Evaluation of response was based on computerized brain scan findings. Thirty-five patients received MOPP and 38 received OPP treatment. There were three complete and six partial remissions among patients receiving MOPP and one complete and five partial remissions among patients receiving OPP. In addition, six patients on MOPP had stable disease for seven to 21 months. Only two patients on OPP had stable disease(6 and 36 months). Most of responses in both treatment regimens occurred in patients with medulloblastoma and astrocytoma. Median duration of remission was nine months for the MOPP and 11 months for the OPP. Two patients on MOPP regimen had fatal myelosuppression. Although the more toxic MOPP regimen produced more responses than OPP in children, differences in the duration of response or survival were not statistically significant (P = .79 and P = .84, respectively).

 

Comments：

This study compared the efficacy of two chemotherapy regimens, MOPP and OPP, in treating recurrent central nervous system tumors in 73 patients under 18 years of age. The patients were stratified into four categories based on the type of tumor they had. The response to treatment was evaluated using computerized brain scans, and it was found that there were more complete and partial remissions in the group that received MOPP compared to the group that received OPP. However, the difference in the duration of response or survival between the two groups was not statistically significant. Additionally, two patients in the MOPP group experienced fatal myelosuppression.

Related Products

Cat.No.	Product Name	Information
S1622	Prednisone	Prednisone is a synthetic corticosteroid agent that is particularly effective as an immunosuppressant compound.

Related Targets

Immunology & Inflammation related Glucocorticoid Receptor